Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.0
-44.94%
20%
—
65.08%
40%
—
5 Years
Score3.0
Net Growth-44.94%
Net Trend20%
Net Income Consistency—
Rev Growth65.08%
Rev Trend40%
Revenue Consistency—
Keros Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 2M to $ 244M and net income went from -$ 45M to $ 87M. Revenue increased in 2 of those 5 years; net income in 1.
Keros Therapeutics Inc currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 11.20 | — |
1 Year2025-08-12 | $ 13.71 | -18.31% |
5 Years2021-08-12 | $ 34.61 | -67.64% |
All Time2020-04-08 | $ 20.08 | -44.22% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-04-08 |
|---|---|---|---|---|
| Price | $ 11.20 | $ 13.71 | $ 34.61 | $ 20.08 |
| Return | — | -18.31% | -67.64% | -44.22% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 33M | -$ 85M | $ 257M |
| 2025 | $ 244M | $ 87M | $ 287M |
| 2024 | $ 3M | -$ 187M | $ 559M |
| 2023 | $ 151K | -$ 152M | $ 331M |
| 2022 | $ 20M | -$ 104M | $ 279M |
| 2021 | $ 20M | -$ 58M | $ 230M |
| IPO2020 | $ 2M | -$ 45M | $ 265M |
Explore beyond KROS
You're looking at Keros Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
